论文部分内容阅读
肺癌是威胁人类健康的常见病和多发病。2014年世界卫生组织最新发布信息宣称:2012年世界新增肺癌患者180万,其中159万人死亡,而中国约占此类病例的1/3以上。因此,对肺癌的预防和治疗研究任重而道远。体部立体定向(SBRT)放疗是近年发展起来的新型放疗技术,与常规放疗相比具有高精度、高剂量、高治疗增益比和靶周正常组织剂量低的优势,其最大的特点在于分割次数减少和单次治疗剂量增加,因此倍受国际关注。非小细胞肺癌(NSCLC)是肺癌中最常见的病理类型,手术切除是早期周围型NSCLC标准治疗方式,但对于不能耐受手术或拒绝手术的患者,SBRT成为首选治疗手段。然而在此领
Lung cancer is a common and frequently-occurring disease that threatens human health. According to the latest WHO release in 2014, 1.8 million lung cancer patients were newly added in 2012, of whom 1.59 million were dead, while China accounted for about one third of such cases. Therefore, the study of prevention and treatment of lung cancer has a long way to go. Stereotactic (SBRT) radiotherapy is a new radiotherapy technique developed in recent years. Compared with conventional radiotherapy, SBRT has the advantages of high precision, high dose, high therapeutic gain ratio and low dose of normal tissue around the target. Reduced and single dose increase, so much international attention. Non-small cell lung cancer (NSCLC) is the most common pathological type in lung cancer. Surgical resection is the standard treatment for early peripheral NSCLC. However, SBRT is the preferred treatment for patients who can not tolerate surgery or who refuse surgery. However, in this collar